摘要
目的研究康复新液对三硝基苯磺酸诱导大鼠溃疡性结肠炎的作用,并初步探讨其作用机制。方法将♂SD大鼠分为正常组、模型组、柳氮磺胺吡啶组和康复新液低、中、高剂量组,以三硝基苯磺酸灌肠诱导大鼠溃疡性结肠炎模型。评估疾病活动指数(DAI)、结肠黏膜损伤指数(CMDI)和病理组织学评分(HS),测定脏器指数、血清IL-4、IL-17,结肠黏膜MPO、EGF、TGF-β1的表达水平等。结果 DAI结果提示造模成功,与正常组比较,模型组IL-4、IL-17、EGF、TGF-β1均明显降低,而CMDI、HS、结肠指数及结肠黏膜MPO均明显升高。康复新液各组DAI、CMDI、HS、结肠黏膜MPO均降低(P<0.05或P<0.01),IL-4、IL-17、EGF、TGF-β1水平明显升高(P<0.01)。结论康复新液灌肠能够有效缓解三硝基苯磺酸诱导的大鼠溃疡性结肠炎,其作用机制可能与下调MPO表达,上调IL-4、IL-17、EGF和TGF-β1水平有关。
Aim To study the effect of the Kangfuxin liquid on 2,4,6-trinitrobenzene sulfonic acid(TNBS)induced ulcerative colitis in rats,and to explore its mechanism.Methods Male SD rats were divided into normal control,model control,SASP groups,and Kangfuxin low,medium and high dose groups.In addition to the normal control group,other groups were induced ulcerative colitis with TNBS solution.Disease activity index(DAI),organ index,colon mucosa damage index(CMDI)and histopathological score(HS),the expression levels of IL-4,IL-17 in serum,and MPO,EGF,TGF-β1 in colonic mucosa were determined.Results The DAI score showed that the model was successful.Compared with the normal group,the level of IL-4 and IL-17,EGF and TGF-β1 in the model group were reduced significantly,while the CMDI score,HS score,colon index and MPO were elevated significantly.The DAI,CMDI,HS and MPO were reduced(P<0.05 or P<0.01),and the levels of IL-4,IL-17,EGF and TGF-β1 increased significantly(P<0.01).Conclusions Kangfuxin liquid can effectively alleviate ulcerative colitis induced by TNBS in rats.The mechanism may be related to the down-regulation of MPO expression and up-regulation of IL-4,IL-17,EGF and TGF-β1 levels.
作者
张汉超
王朋川
刘衡
耿福能
马秀英
何苗
张成桂
李玥
ZHANG Han-chao;WANG Peng-chuan;LIU Heng;GENG Fu-neng;MA Xiu-ying;HE Miao;ZHANG Cheng-gui;LI Yue(Yunnan Provincial Key Lab of Entomological Biopharmaceutical R&D,Dali Yunnan 671000,China;National-Local Joint Engineering Research Center of Entomoceutics,Dali Yunnan 671000,China;Yunnan Provincial 2011 Collaborative Innovation Center for Entomoceutics,Dali Yunnan 671000,China;Good Doctor Pharmaceutical Group,Chengdu 610000,China)
出处
《中国药理学通报》
CAS
CSCD
北大核心
2018年第4期496-501,共6页
Chinese Pharmacological Bulletin
基金
国家自然科学基金资助项目(No 81660605)
药用特种昆虫开发国家地方联合工程研究中心创新能力建设项目(云发改高技[2015]395)
云南省昆虫生物医药研发重点实验室专项经费(No 2015DG030)
云南省2011协同创新中心项目([2012]25)
云南省应用基础研究重点项目(No2014FA007)